Altimmune (NasdaqGM:ALT) - Share price, News & Analysis

ALT fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ALT Stock Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

Rewards

Revenue is forecast to grow 86.43% per year

Risk Analysis

Earnings are forecast to decline by an average of 13.8% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

+ 1 more risk

Altimmune Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Altimmune
Historical stock prices
Current Share Price	US$10.60
52 Week High	US$17.26
52 Week Low	US$3.83
Beta	1.43
1 Month Change	124.58%
3 Month Change	65.88%
1 Year Change	-34.57%
3 Year Change	358.87%
5 Year Change	-88.14%
Change since IPO	-95.53%

Shareholder Returns

	ALT	US Biotechs	US Market
7D	44.4%	11.9%	4.0%
1Y	-34.6%	-25.1%	-20.5%

Return vs Industry: ALT underperformed the US Biotechs industry which returned -26.6% over the past year.

Return vs Market: ALT underperformed the US Market which returned -20.8% over the past year.

Price Volatility

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement	15.8%
Biotechs Industry Average Movement	12.9%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ALT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ALT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1997	47	Vipin Garg	https://altimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

Altimmune Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
ALT fundamental statistics
Market Cap	US$454.88m
Earnings (TTM)	-US$101.66m
Revenue (TTM)	US$3.60m

126.2x

P/S Ratio

-4.5x

P/E Ratio

Is ALT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALT income statement (TTM)
Revenue	US$3.60m
Cost of Revenue	US$79.73m
Gross Profit	-US$76.12m
Other Expenses	US$25.53m
Earnings	-US$101.66m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.37
Gross Margin	-2,111.97%
Net Profit Margin	-2,820.39%
Debt/Equity Ratio	0%

How did ALT perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is ALT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALT?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ALT. This is calculated by dividing ALT's market cap by their current preferred multiple.
What is ALT's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$454.88m

ALT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	76.7x
Enterprise Value/EBITDA	-3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ALT's PB Ratio compare to its peers?

ALT PB Ratio vs Peers

The above table shows the PB ratio for ALT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	6.4x

Price-To-Book vs Peers: ALT is good value based on its Price-To-Book Ratio (2.5x) compared to the peer average (6.4x).

Price to Earnings Ratio vs Industry

How does ALT's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Book vs Industry: ALT is expensive based on its Price-To-Book Ratio (2.5x) compared to the US Biotechs industry average (1.5x)

Price to Book Ratio vs Fair Ratio

What is ALT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALT's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ALT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-13.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALT's revenue (86.4% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: ALT's revenue (86.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Altimmune performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-22.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALT is currently unprofitable.

Growing Profit Margin: ALT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.

Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: ALT has a negative Return on Equity (-54.99%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Altimmune's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALT's short term assets ($191.1M) exceed its short term liabilities ($19.1M).

Long Term Liabilities: ALT's short term assets ($191.1M) exceed its long term liabilities ($1.7M).

Debt to Equity History and Analysis

Debt Level: ALT is debt free.

Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 14.5%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALT has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 45% each year.

Discover healthy companies

Dividend

What is Altimmune current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure

CEO

Vipin Garg (63 yo)

3.58yrs

Tenure

US$2,631,639

Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

CEO Compensation Analysis

Compensation vs Market: Vipin's total compensation ($USD2.63M) is about average for companies of similar size in the US market ($USD2.77M).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ALT's management team is considered experienced (3.8 years average tenure).

Board Members

Experienced Board: ALT's board of directors are considered experienced (5.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ALT insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/23 00:00
End of Day Share Price	2022/06/23 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31